全球寡核苷酸合成市場

全球寡核苷酸合成市場預計到2030年將達到199億美元

2024年全球寡核苷酸合成市場規模估計為83億美元，預計在分析期間（2024-2030年）將以15.6%的複合年成長率成長，到2030年將達到199億美元。本報告分析的細分市場之一－基於寡核苷酸的藥物，預計將以17.3%的複合年成長率成長，到分析期末將達到86億美元。合成寡核苷酸細分市場預計在分析期間將以15.0%的複合年成長率成長。

美國市場規模估計為22億美元，中國市場預計將以21.2%的複合年成長率成長。

預計到2024年，美國寡核苷酸合成市場規模將達22億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到49億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到21.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期內，這兩個市場的複合年成長率將分別達到11.1%和13.1%。在歐洲，德國的複合年成長率預計將達到約12.2%。

全球寡核苷酸合成市場—主要趨勢與促進因素概述

什麼是寡核苷酸合成？為什麼它引起了全世界的關注？

寡核苷酸合成是指用於建構短核苷酸序列（DNA和RNA的基本組成單元）的化學過程。這些合成寡核苷酸對於從診斷和治療到基因研究和生物技術等多種應用至關重要。透過合成過程客製化DNA和RNA鏈的能力徹底改變了分子生物學，使研究人員能夠設計特定的序列用於標靶基因介入、基因編輯和藥物開發。寡核苷酸在現代生物技術中發揮關鍵作用，支持PCR（聚合酵素鏈鎖反應）、DNA序列測定、基因合成和反義核酸治療藥物等應用。作為一項關鍵的實行技術，寡核苷酸合成為基因組學、個人化醫療和藥物發現領域的突破奠定了基礎，使其成為生命科學和醫療保健領域不可或缺的一部分。

科技如何推動寡核苷酸合成的發展？

技術進步在寡核苷酸合成的發展歷程中發揮了關鍵作用，顯著提高了生產過程的精確度、可擴展性和效率。自動化合成儀和改進的固相合成方法等創新技術大大加快了寡核苷酸的生產速度，使其更容易滿足製藥和生物技術行業日益成長的需求。此外，高通量合成技術的最新進展使得大規模寡核苷酸庫的平行生產成為可能，從而推動了基因編輯和CRISPR技術等領域的快速研究。次世代定序儀（NGS）技術的出現進一步增加了對高品質寡核苷酸的需求，因為精確的客製化序列在NGS工作流程中至關重要。各公司正投入大量資金提高合成寡核苷酸的純度、長度和序列保真度，不斷拓展基因研究和分子診斷領域的應用邊界。

為什麼寡核苷酸對治療和診斷至關重要？

人們對寡核苷酸在治療和診斷應用方面的興趣日益濃厚，這是推動市場發展的關鍵因素。在治療領域，寡核苷酸被用於建構反義寡核苷酸（ASO）、小干擾RNA（siRNA）和適配體，這些分子均能調節基因表現和蛋白質功能。目前，這些治療方法正被研究用於治療遺傳性疾病、癌症和罕見疾病，為人們提供了一類新型的高標靶化、個人化藥物。此外，在診斷領域，合成寡核苷酸對於開發用於檢測基因突變、病原體和生物標記的檢測方法至關重要。例如，新冠肺炎疫情凸顯了寡核苷酸在診斷測試（如PCR檢測）開發中的關鍵作用，這些測試依賴於短的、客製化設計的DNA引子。基因治療、免疫療法和精準醫療的快速發展，正在催生對客製化寡核苷酸合成服務的強勁需求，進一步鞏固了該技術在推動醫療保健發展中的作用。

推動寡核苷酸合成市場成長的關鍵因素是什麼？

寡核苷酸合成市場的成長受多種因素驅動，每個因素都對市場擴張做出獨特的貢獻。其中一個關鍵因素是治療藥物研發，特別是針對罕見疾病和複雜疾病的基因療法，合成寡核苷酸的需求不斷增加。 CRISPR和基因編輯技術的快速發展也推動了對高品質寡核苷酸的需求，這些寡核苷酸可用作引導RNA和其他基因操作的關鍵組件。個人化醫療領域的不斷發展，根據患者的個別基因譜量身訂做治療方案，進一步推動了對客製化寡核苷酸合成的需求。此外，次世代定序儀和分子診斷技術的廣泛應用也顯著擴大了用於診斷檢測和研究的寡核苷酸市場。自動化和高通量合成等製造技術的進步，使企業能夠以更低的成本更有效率地生產寡核苷酸，從而使更多研究人員和製藥公司能夠獲得寡核苷酸。在可預見的未來，對生物技術的持續投資和對基因組學日益成長的興趣預計將支撐該市場的強勁成長。

部分

產品（基於寡核苷酸的藥物、合成寡核苷酸、試劑、器械）、應用（治療、診斷、研究）、最終用途（醫院、診斷實驗室、製藥和生物技術公司、其他最終用途）

受訪公司範例

• ATDBio Ltd.
• Bio-Synthesis Inc.
• Eurogentec
• GE Healthcare Life Sciences
• GeneDesign, Inc.
• GenScript Biotech Corporation
• Integrated DNA Technologies（IDT）, Inc.
• LGC Biosearch Technologies
• Merck KgaA
• Nitto Denko Avecia Inc.
• Thermo Fisher Scientific, Inc.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具，革新市場和競爭情報。

全球行業分析師並沒有遵循典型的LLM或特定行業的SLM查詢，而是建立了一個內容庫，其中收集了來自世界各地專家的資訊，包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師預測，企業的競爭地位將根據其總部所在國家、製造地以及進出口（成品和OEM）情況而改變。這種複雜多變的市場動態預計將從多個方面影響競爭對手，包括銷貨成本成本上升、盈利下降以及供應鏈重組等，以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章 市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 澳洲
• 印度
• 韓國
• 亞太其他地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Oligonucleotide Synthesis Market to Reach US$19.9 Billion by 2030

The global market for Oligonucleotide Synthesis estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.9 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Oligonucleotide-Based Drugs, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Synthesized Oligonucleotides segment is estimated at 15.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 21.2% CAGR

The Oligonucleotide Synthesis market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 21.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Oligonucleotide Synthesis Market - Key Trends & Drivers Summarized

What Is Oligonucleotide Synthesis and Why Is It Gaining Global Attention?

Oligonucleotide synthesis refers to the chemical process used to create short sequences of nucleotides, the building blocks of DNA and RNA. These synthetic oligonucleotides are essential for a variety of applications, ranging from diagnostics and therapeutics to genetic research and biotechnology. The ability to custom-build DNA or RNA strands through synthetic processes has revolutionized molecular biology, allowing researchers to design specific sequences for targeted genetic interventions, gene editing, and pharmaceutical development. Oligonucleotides play a crucial role in modern biotechnology, supporting applications such as PCR (polymerase chain reaction), DNA sequencing, gene synthesis, and antisense therapeutics. As a key enabling technology, oligonucleotide synthesis underpins breakthroughs in genomics, personalized medicine, and drug discovery, making it indispensable to life sciences and healthcare.

How Is Technology Shaping the Evolution of Oligonucleotide Synthesis?

Technological advancements have been pivotal in the evolution of oligonucleotide synthesis, driving higher precision, scalability, and efficiency in the production process. Innovations such as automated synthesizers and improved solid-phase synthesis methods have significantly accelerated the rate at which oligonucleotides can be manufactured, making it easier to meet the growing demands of pharmaceutical and biotechnology industries. Additionally, recent developments in high-throughput synthesis technology allow for the parallel production of large libraries of oligonucleotides, enabling faster research in fields like gene editing and CRISPR technology. The advent of next-generation sequencing (NGS) technologies has further heightened the need for high-quality oligonucleotides, as precise and custom-designed sequences are critical for NGS workflows. Companies are investing heavily in enhancing the purity, length, and sequence fidelity of synthesized oligonucleotides, pushing the boundaries of what can be achieved in genetic research and molecular diagnostics.

Why Are Oligonucleotides Essential in Therapeutics and Diagnostics?

The rising interest in oligonucleotides for therapeutic and diagnostic applications has been a significant driver for the market. In therapeutics, oligonucleotides are used to create antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, all of which can modulate gene expression or protein function. These therapies are being explored for the treatment of genetic disorders, cancers, and rare diseases, offering a new class of drugs that are highly targeted and personalized. Additionally, in diagnostics, synthetic oligonucleotides are critical in the development of assays for detecting genetic mutations, pathogens, and biomarkers. The COVID-19 pandemic, for example, highlighted the critical role of oligonucleotides in the development of diagnostic tests such as PCR assays, which rely on short, custom-designed DNA primers. The rapid expansion of gene therapy, immunotherapy, and precision medicine has created a robust demand for custom oligonucleotide synthesis services, further cementing the role of this technology in advancing healthcare.

What Are the Major Drivers Fueling the Growth of the Oligonucleotide Synthesis Market?

The growth in the oligonucleotide synthesis market is driven by several factors, each contributing uniquely to its expansion. One of the primary drivers is the increasing demand for synthetic oligonucleotides in therapeutic development, particularly for genetic therapies aimed at treating rare and complex diseases. The rapid rise of CRISPR and gene-editing technologies has also fueled the need for high-quality oligonucleotides that can be used as guide RNAs and other components essential for gene manipulation. The growing field of personalized medicine, where treatments are tailored to the genetic profile of individual patients, is further driving the demand for custom oligonucleotide synthesis. Additionally, the widespread adoption of next-generation sequencing and molecular diagnostics has significantly expanded the market for oligonucleotides used in diagnostic assays and research. With advancements in manufacturing technologies, including automation and high-throughput synthesis, companies can now produce oligonucleotides more efficiently and at lower costs, making them accessible to a broader range of researchers and pharmaceutical companies. The continued investment in biotechnology, coupled with an increasing focus on genomics, is expected to sustain robust growth in this market for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Oligonucleotide Synthesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Equipment); Application (Therapeutics, Diagnostics, Research); End-Use (Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• ATDBio Ltd.
• Bio-Synthesis Inc.
• Eurogentec
• GE Healthcare Life Sciences
• GeneDesign, Inc.
• GenScript Biotech Corporation
• Integrated DNA Technologies (IDT), Inc.
• LGC Biosearch Technologies
• Merck KgaA
• Nitto Denko Avecia Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Oligonucleotide Synthesis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Custom Oligonucleotides in Research and Diagnostics Propels Growth of the Oligonucleotide Synthesis Market Globally
  • Increased Focus on Gene Editing Technologies, Including CRISPR, Drives the Adoption of Advanced Oligonucleotide Synthesis Techniques
  • Growing Investment in Genomics and Proteomics Research Expands the Addressable Market Opportunity for Oligonucleotide Synthesis Services
  • Surging Use of Oligonucleotides as Therapeutic Agents in Oncology and Rare Diseases Spurs Growth in Oligonucleotide Synthesis
  • Technological Advancements in Automated and High-Throughput Oligonucleotide Synthesizers Propel Efficiency and Accelerate Market Growth
  • Rising Interest in Personalized Medicine and Precision Therapies Strengthens the Business Case for Oligonucleotide Synthesis in Clinical Applications
  • Increased Adoption of Oligonucleotides in Molecular Diagnostics and Pathogen Detection Generates Demand for Efficient Synthesis Platforms
  • Growing Demand for Antisense Oligonucleotides and siRNA Therapeutics Creates New Opportunities for Oligonucleotide Synthesis Providers
  • Expansion of Gene Therapy and Vaccine Development Using Synthetic Oligonucleotides Drives Long-Term Growth in the Market
  • Increasing Use of Oligonucleotides in Agricultural Biotechnology Expands Market Opportunities Beyond
  • Enhanced Stability and Delivery Technologies for Oligonucleotides Propel Growth in Therapeutic Applications
  • Stringent Regulatory Requirements for Oligonucleotide Synthesis in Therapeutics and Diagnostics Create Challenges and Drive Innovation in Quality Control
  • The Growing Shift Toward Synthetic Biology and DNA Data Storage Systems Generates Demand for High-Fidelity Oligonucleotide Synthesis
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oligonucleotide Synthesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oligonucleotide-Based Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Synthesized Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION